Collectively, this study delineates key biomarkers and cellular mediators of immune dysregulation in IBC, elucidates TME remodeling processes, and establishes GZMB and SPP1 as potential prognostic biomarkers for IBC patients. This evidence concerns the gene GZMB and inflammatory breast carcinoma.